000109688 001__ 109688 000109688 005__ 20230519145550.0 000109688 0247_ $$2doi$$a10.3390/ph14070603 000109688 0248_ $$2sideral$$a126730 000109688 037__ $$aART-2021-126730 000109688 041__ $$aeng 000109688 100__ $$aPerez-Laguna, V 000109688 245__ $$aPhotodynamic Therapy Combined with Antibiotics or Antifungals against Microorganisms That Cause Skin and Soft Tissue Infections: A Planktonic and Biofilm Approach to Overcome Resistances 000109688 260__ $$c2021 000109688 5060_ $$aAccess copy available to the general public$$fUnrestricted 000109688 5203_ $$aThe present review covers combination approaches of antimicrobial photodynamic therapy (aPDT) plus antibiotics or antifungals to attack bacteria and fungi in vitro (both planktonic and biofilm forms) focused on those microorganisms that cause infections in skin and soft tissues. The combination can prevent failure in the fight against these microorganisms: antimicrobial drugs can increase the susceptibility of microorganisms to aPDT and prevent the possibility of regrowth of those that were not inactivated during the irradiation; meanwhile, aPDT is effective regardless of the resistance pattern of the strain and their use does not contribute to the selection of antimicrobial resistance. Additive or synergistic antimicrobial effects in vitro are evaluated and the best combinations are presented. The use of combined treatment of aPDT with antimicrobials could help overcome the difficulty of fighting high level of resistance microorganisms and, as it is a multi-target approach, it could make the selection of resistant microorganisms more difficult. 000109688 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B10-17R$$9info:eu-repo/grantAgreement/ES/ISCIII-REIPI/RD16-0016-0001 000109688 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000109688 590__ $$a5.215$$b2021 000109688 592__ $$a0.851$$b2021 000109688 594__ $$a4.0$$b2021 000109688 591__ $$aPHARMACOLOGY & PHARMACY$$b69 / 279 = 0.247$$c2021$$dQ1$$eT1 000109688 593__ $$aPharmaceutical Science$$c2021$$dQ1 000109688 591__ $$aCHEMISTRY, MEDICINAL$$b16 / 63 = 0.254$$c2021$$dQ2$$eT1 000109688 593__ $$aDrug Discovery$$c2021$$dQ1 000109688 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000109688 700__ $$aGarcia-Luque, I 000109688 700__ $$aBallesta, S 000109688 700__ $$0(orcid)0000-0001-7294-245X$$aRezusta López, A$$uUniversidad de Zaragoza 000109688 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte Calzada, Y$$uUniversidad de Zaragoza 000109688 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología 000109688 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología 000109688 773__ $$g14, 7 (2021), 603 [21 pp]$$pPharmaceuticals$$tPharmaceuticals$$x1424-8247 000109688 8564_ $$s668581$$uhttps://zaguan.unizar.es/record/109688/files/texto_completo.pdf$$yVersión publicada 000109688 8564_ $$s2689437$$uhttps://zaguan.unizar.es/record/109688/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000109688 909CO $$ooai:zaguan.unizar.es:109688$$particulos$$pdriver 000109688 951__ $$a2023-05-18-15:50:00 000109688 980__ $$aARTICLE